An interventional study of Genicular Radiofrequency Ablation and Sham Genicular Radiofrequency Ablation in Osteoarthritis, Knee, sponsored by University of Calgary. Active, not recruiting at 1 site in Canada. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by University of Calgary · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies in Osteoarthritis, Knee with a site in Canada — 28 open to participants now, 40 under way, 6 of them phase 3. Osteoarthritis, Knee · Canada.
Among the 171 studies in Osteoarthritis, Knee with a site in Canada, this one is the 104th largest by planned enrollment of the 160 interventional ones that give a count, is one of 8 that started in 2022, is one of 100 with no phase, reaches primary completion later than 14 of the 39 other live ones, and was the 129th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →28 of the 171 studies in Osteoarthritis, Knee with a site in Canada are open now. Recruiting first, the newest first:
Pfizer · Sites in Canada, United States
Ages 18+
Novo Nordisk A/S · Sites in Canada, United States, Australia and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Canada, United States, Australia and 7 more countries
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 40–80
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 29 · Phase 3 25 · Phase 4 10
First in 1999; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 44 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 63 across the 160 interventional studies, 48 across the 10 observational. Of the 106 that completed or were terminated, 29 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 171 have an industry lead sponsor. The 10 most frequent:
University of Calgary is the lead sponsor of 704 studies on the registry; 197 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.
University of Calgary has 8 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
14 of the studies in Osteoarthritis, Knee with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05283889University of CalgaryGenicular Radiofrequency Ablation Following Total Knee Arthroplasty | 2026-12 |
| NCT04378049McMaster UniversityRobot-Assisted Partial Knee Replacement Versus Standard Total Knee Replacement | 2026-12 |
| NCT01674816Centre hospitalier de l'Université de Montréal (CHUM)Minimally Invasive Three-dimensional Knee Kinematic Assessment and Surgical Guidance Using Ultrasonic Rigid Registration | 2026-12-01 |
| NCT06166628David ClinkardGenicular Artery Embolization vs Nerve Ablation Intervention (GENI) for Knee Osteoarthritis | 2026-12-01 |
| NCT06195423University of British ColumbiaStopping OsteoARthritis After an ACL Tear | 2026-12-30 |
Add all 14 to your calendar (.ics) → With an account.
Among the 171 studies in Osteoarthritis, Knee with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Currently, nearly 1 million total knee arthroplasties (TKA) are performed yearly in the United States. Three million are projected to be performed in 2040. Between 15-30% of all patients who undergo TKA have continued pain, reduced quality of life and functional impairments that cannot be attributed to hardware failure/loosening or infection. Treatment options for persistent post TKA pain (failed TKA) are limited. There is a need for minimally invasive, and effective pain and disability modulating interventions for patients with failed TKA. Genicular radiofrequency ablation (GRFA) has been described, refined, and validated as an effective minimally invasive intervention to control refractory knee pain secondary to knee osteoarthritis (OA) as evidenced by three favorable meta-analyses published in 2021 alone.3-5 GRFA is a minimally invasive percutaneous procedure that utilizes thermal energy to coagulate nerves from the knee. Though sometimes used in practice, there is limited research describing and evaluating GRFA for patients with failed TKA. This will be the first trial to evaluate the safety and efficacy of GRFA in patients with failed TKA using a robust study design and up-to-date, evidence-based selection criteria and technique.
The general objective of this study is to determine the safety and efficacy of GRFA in patients with failed TKA. The central hypothesis is that GRFA is safe and more efficacious in improving pain and function than sham GRFA. A triple blinded randomized sham-controlled trial design will be used. Patients with failed TKA will be recruited and randomized into either a thermal or sham GRFA group. Patient selection criteria and GRFA procedural technique will incorporate refinements based on expanded understanding from recent research. Outcomes will be assessed prior to and at 3, 6 and 12 months post-GRFA. The primary outcome measures will be between group difference in the change in pain (NRS) between pre- and 6 months post. Secondary outcomes will include safety and changes in function (WOMAC; sit-stand test; strength; range of motion \& balance), participants' impression of change, perceived need for revision arthroplasty, analgesic use, and quality-of-life. Crossover will be offered to participants in the sham group at 6 months post-treatment. Data will be analyzed using descriptive, linear mixed-effects model and Kaplan-Meier Survival Curve statistics. The proposed research is innovative and important as it uses a robust study design to evaluate the safety and efficacy of an emerging RFA intervention in a prevalent suffering patient population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After the cannulae are placed and tines deployed, a single lesion (30 second ramp-up time; 80C x 2 minutes) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
Procedure: Genicular Radiofrequency Ablation
The same procedure will be employed as per Group 1 - However, the sham procedure will involve no electrical signal applied to the participant.
Procedure: Sham Genicular Radiofrequency Ablation
After the cannulae are placed and tines deployed, a single lesion (30 second ramp-up time; 80C x 2 minutes) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
After the cannulae are placed and tines deployed, a single lesion (no electrical signal applied to patient) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
Average Pain Intensity Over the Prior week (0 - 10)
Numerical pain rating scale (0 - 10) with higher scores indicating a worse outcome
Time frame: 6 months
Change in pain intensity between pre- and 6-months post-intervention
Numerical Pain rating scale (NPRS) 6 month minus NPRS pre-intervention, with increased negative scores indicating a better outcome
Time frame: 6 months
Average Pain Intensity Over the Prior Week (0 - 10)
Numerical pain rating scale (0 - 10) with higher scores indicating worse outcomes
Time frame: 3 and 12-months post-intervention
Western Ontario and McMaster Universities Arthritis Index (WOMAC)
Measure of pain (0 - 20), stiffness (0 - 8) and physical function (0 - 68) with higher scores indicating wore pain, stiffness and functional limitations
Time frame: 3, 6 and 12-months post-intervention
The Clinical Global Impressions Scale (CGI)
Patient reported global impression of change (1 = Very Much Improved to 7 = Very Much Worse)
Time frame: 3, 6 and 12-months post-intervention
Safety - Adverse Events
Presence of self-reported complications
Time frame: 1-week, 3, 6 and 12-months post-intervention
Proportion of participants exceeding 50% pain relief
Proportion of participants that experience ≥ 50% pain relief
Time frame: 6 months
Proportion of participants exceeding Minimal Clinically Important Difference (MCID) pain relief
Proportion of participants that experience MCID knee pain relief
Time frame: 6 months
Perceived Need for Revision Arthroplasty
"If revision surgery of your knee replacement was available to you, how interested would you be in having it at this time?" Y or N
Time frame: Baseline (Prior to), 3, 6 and 12-months post-intervention
Analgesic Use
Quantitative Analgesic Questionnaire
Time frame: Baseline (Prior to), 3, 6 and 12-months post-intervention
Health-related Quality of Life
EQ-5D-5L
Time frame: Baseline (Prior to), 3, 6 and 12-months post-intervention
Plan to share: No
Started May 2022 (actual). Primary completion is estimated for Dec 2026, 55 months after the start.
Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 55 months is above that.
Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.